Hengrui Therapeutics Inc., a Princeton, N.J.-based oncology drug startup, raised $100m in funding.
The backer was HR Bio Holdings Limited, a joint venture between Jiangsu Hengrui Medicine Co. Ltd.* and an undisclosed blue chip investment firm.
The proceeds from the investment will be used to advance clinical trials in the company’s current areas of pharmaceutical research and development.
Led by Adam Zong, PhD, President and CEO, and Mr. Piaoyang Sun, JHM and HTI Chairman, HTI is a recently formed biopharmaceutical company engaged in the development and commercialization of innovative cancer therapies. its drug pipeline consists of multiple clinical-staged oncology and immuno-oncology assets.
* Jiangsu Hengrui Medicine Co. Ltd. is the largest ethical pharmaceutical company in China, specializing in multiple therapeutic areas such as oncology, endocrinology, cardiovascular and metabolic disorders, surgical products, and imaging agents. It is publicly traded on the Shanghai Security Exchange (Code: 600276).
FinSMEs
23/06/2016